179626-19-8

Basic information

• Product Name: 2-amino-N-[2,4-dichloro-3-({[2-methyl-4-(4-morpholinyl)-8-quinolinyl]oxy}methyl)phenyl]-N-methylacetamide
• Synonyms: 2-amino-N-[2,4-dichloro-3-({[2-methyl-4-(4-morpholinyl)-8-quinolinyl]oxy}methyl)phenyl]-N-methylacetamide
• CAS NO: 179626-19-8
• Molecular Weight: 489.401
• Mol File: 179626-19-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-amino-N-[2,4-dichloro-3-({[2-methyl-4-(4-morpholinyl)-8-quinolinyl]oxy}methyl)phenyl]-N-methylacetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-N-[2,4-dichloro-3-({[2-methyl-4-(4-morpholinyl)-8-quinolinyl]oxy}methyl)phenyl]-N-methylacetamide(179626-19-8)
• EPA Substance Registry System: 2-amino-N-[2,4-dichloro-3-({[2-methyl-4-(4-morpholinyl)-8-quinolinyl]oxy}methyl)phenyl]-N-methylacetamide(179626-19-8)

Safety Data

• Hazardous Substances Data: 179626-19-8(Hazardous Substances Data)

Upstream product

• 167837-48-1 N-(2,4-dichloro-3-(hydroxymethyl)phenyl)-2-(1,3-dioxoisoindolin-2-yl)-N-methylacetamide 
• 167837-49-2 2,6-dichloro-1-methylsulfonyloxymethyl-3-[N-methyl-N-(phthalimidoacetyl)amino]benzene 
• 179626-56-3 2-methyl-4-(4-morpholinyl)-8-quinolinol 
• 28507-46-2 4-chloro-8-hydroxy-2-methylquinoline 
• 179626-16-5 N-[2,4-dichloro-3-({[2-methyl-4-(4-morpholinyl)-8-quinolinyl]oxy}methyl)phenyl]-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-methylacetamide 

Downstream Products

• 179624-53-4 ethyl 5-[(1E)-3-({2-[2,4-dichloro(methyl)-3-({[2-methyl-4-(4-morpholinyl)-8-quinolinyl]oxy}methyl)anilino]-2-oxoethyl}amino)-3-oxo-1-propenyl]-2-pyridinecarboxylate 
• 179624-69-2 5-[(1E)-3-({2-[2,4-dichloro(methyl)-3-({[2-methyl-4-(4-morpholinyl)-8-quinolinyl]oxy}methyl)anilino]-2-oxoethyl}amino)-3-oxo-1-propenyl]-2-pyridinecarboxylic acid 

Relevant articles and documents

A New Class of Nonpeptide Bradykinin B2 Receptor Ligand, Incorporating a 4-Aminoquinoline Framework. Identification of a Key Pharmacophore to Determine Species Difference and Agonist/Antagonist Profile

Introduction of various aliphatic amino groups at the 4-position of the quinoline moiety of our nonpeptide bradykinin (BK) B2 receptor antagonists afforded highly potent ligands for human B2 receptor with various affinities for guine